GBT Global Blood Therapeutics Inc

Price (delayed)

$31.79

Market cap

$2.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.87

Enterprise value

$2.33B

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is ...

Highlights
Global Blood Therapeutics's gross profit has increased by 42% YoY and by 8% from the previous quarter
GBT's revenue is up by 42% year-on-year and by 8% since the previous quarter
The debt has soared by 182% year-on-year
GBT's equity has shrunk by 63% YoY and by 32% QoQ

Key stats

What are the main financial stats of GBT
Market
Shares outstanding
65.1M
Market cap
$2.07B
Enterprise value
$2.33B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
15.38
Price to sales (P/S)
9.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.04
Earnings
Revenue
$210.87M
EBIT
-$288.95M
EBITDA
-$280.11M
Free cash flow
-$251.77M
Per share
EPS
-$4.87
Free cash flow per share
-$3.88
Book value per share
$2.07
Revenue per share
$3.25
TBVPS
$13.41
Balance sheet
Total assets
$869.54M
Total liabilities
$735.54M
Debt
$653.16M
Equity
$134M
Working capital
$596.34M
Liquidity
Debt to equity
4.87
Current ratio
8.52
Quick ratio
7.36
Net debt/EBITDA
-0.92
Margins
EBITDA margin
-132.8%
Gross margin
98.2%
Net margin
-146.8%
Operating margin
-137.3%
Efficiency
Return on assets
-40.9%
Return on equity
-129.7%
Return on invested capital
-44.5%
Return on capital employed
-36.6%
Return on sales
-137%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GBT stock price

How has the Global Blood Therapeutics stock price performed over time
Intraday
2.78%
1 week
19.33%
1 month
23.79%
1 year
-12.76%
YTD
8.61%
QTD
-8.23%

Financial performance

How have Global Blood Therapeutics's revenue and profit performed over time
Revenue
$210.87M
Gross profit
$207.08M
Operating income
-$289.59M
Net income
-$309.58M
Gross margin
98.2%
Net margin
-146.8%
Global Blood Therapeutics's gross profit has increased by 42% YoY and by 8% from the previous quarter
GBT's revenue is up by 42% year-on-year and by 8% since the previous quarter
The net income has decreased by 24% YoY and by 2.1% QoQ
Global Blood Therapeutics's operating income has decreased by 20% YoY

Growth

What is Global Blood Therapeutics's growth rate over time

Valuation

What is Global Blood Therapeutics stock price valuation
P/E
N/A
P/B
15.38
P/S
9.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.04
The EPS has contracted by 21% YoY
The P/B is 144% above the 5-year quarterly average of 6.3 and 60% above the last 4 quarters average of 9.6
GBT's equity has shrunk by 63% YoY and by 32% QoQ
GBT's revenue is up by 42% year-on-year and by 8% since the previous quarter
GBT's price to sales (P/S) is 8% lower than its last 4 quarters average of 10.6

Efficiency

How efficient is Global Blood Therapeutics business performance
The company's return on equity has shrunk by 125% YoY and by 27% QoQ
The company's return on invested capital rose by 29% YoY and by 25% QoQ
The ROA has contracted by 14% YoY but it has grown by 5% from the previous quarter
The ROS has grown by 14% YoY and by 7% from the previous quarter

Dividends

What is GBT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GBT.

Financial health

How did Global Blood Therapeutics financials performed over time
Global Blood Therapeutics's total assets is 18% higher than its total liabilities
Global Blood Therapeutics's total liabilities has surged by 157% YoY
Global Blood Therapeutics's total assets has increased by 34% YoY but it has decreased by 7% QoQ
The debt has soared by 182% year-on-year
GBT's equity has shrunk by 63% YoY and by 32% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.